Form 4: DarioHealth CEO Awarded Shares Amid Reverse Stock Split

DarioHealth Corp.'s CEO, Erez Raphael, received a restricted share award of 60,000 common shares following a 20-for-1 reverse stock split.

Summary

• DarioHealth Corp. (DRIO) CEO and Director, Erez Raphael, was granted a restricted share award of 60,000 common shares on September 11, 2025.
• The restricted share award will vest in two equal installments on the last day of each successive annual anniversary after the grant date, over a two-year period.
• The company completed a 20-for-1 reverse stock split on August 28, 2025, which is reflected in the reported beneficial ownership.
• Following the transaction, Erez Raphael directly beneficially owns 156,853 common shares.
• Additionally, Erez Raphael indirectly beneficially owns 1,894 common shares through Dicilyon Consulting and Investment Ltd.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the significant reverse stock split, which often indicates underlying financial or market challenges. While the CEO's share award is a positive for management alignment, it does not outweigh the implications of the reverse split for overall company health and investor perception.

Positives

• The grant of 60,000 restricted shares to the CEO aligns management's interests with long-term shareholder value through a multi-year vesting schedule.
• The award at a $0 price indicates it is a compensation grant, which is a common practice for executive incentives.

Negatives

• The 20-for-1 reverse stock split, typically implemented to boost share price and meet listing requirements, often signals underlying challenges or a significantly depressed stock valuation.
• A reverse stock split can sometimes lead to reduced liquidity and investor confidence, as it does not fundamentally change the company's market capitalization.

Risks

• The reverse stock split may not sustainably improve the company's stock price or market perception, potentially leading to further declines if underlying business performance does not improve.
• Shareholders may experience a decrease in liquidity due to fewer outstanding shares post-split.
• The effectiveness of the restricted share award as an incentive depends on the company's future performance and stock price appreciation, which remains uncertain.

Future Outlook

The restricted share award granted to CEO Erez Raphael is structured to vest in two equal annual installments over a two-year period, starting from September 11, 2025, indicating a forward-looking incentive for management performance.

Industry Context

Reverse stock splits are often observed in companies whose stock prices have fallen significantly, potentially below minimum exchange listing requirements. While they increase the per-share price, they do not alter the company's fundamental valuation or market capitalization. The grant of restricted stock to the CEO is a standard practice for executive compensation, aiming to align leadership incentives with long-term company performance, particularly in growth-oriented or turnaround situations.

Comparison to Industry Standards

• A 20-for-1 reverse stock split is a significant consolidation, often more aggressive than typical splits (e.g., 1-for-5 or 1-for-10) seen in companies like Rite Aid (RAD) or Bed Bath & Beyond (BBBY) before their delistings, suggesting a substantial need to boost share price.
• Executive equity awards with multi-year vesting schedules are standard across industries, comparable to practices at companies like Teladoc Health (TDOC) or Livongo Health (acquired by Teladoc), which operate in similar digital health sectors, aiming to retain talent and incentivize long-term growth.

Related Party Transactions

• Erez Raphael, as CEO and Director, received a restricted share award from DarioHealth Corp., which is a transaction between the company and a related party (executive management).
• Erez Raphael's indirect beneficial ownership of 1,894 common shares is held through Dicilyon Consulting and Investment Ltd., indicating a related entity.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares, increasing the per-share price but not the overall market capitalization, which can be perceived negatively and potentially impact liquidity. The CEO's share award aligns management incentives with shareholder value over the long term.
• Management: The CEO receives a significant equity award, incentivizing long-term performance and retention.

Next Steps

• The restricted share award will vest in two equal installments on the last day of each successive annual anniversary after September 11, 2025, over a two-year period.

Key Dates

Recommendation

While the CEO's equity award provides a positive signal for management alignment, the 20-for-1 reverse stock split is a strong negative indicator, often associated with companies facing significant challenges. Investors should hold and monitor for fundamental improvements in business operations and financial performance before considering further investment, as the reverse split alone does not address underlying issues.

Keywords

DarioHealth, DRIO, Erez Raphael, Restricted Stock Award, Reverse Stock Split, CEO Compensation, SEC Form 4, Beneficial Ownership, Equity Compensation